April 1 (Reuters) - Connect Biopharma Holdings Ltd CNTB.O:
CONNECT BIOPHARMA ANNOUNCES POSITIVE TYPE C MEETING WITH THE FDA FOR RADEMIKIBART
CONNECT BIOPHARMA HOLDINGS LTD - TRIALS EXPECTED TO INITIATE IN Q2 2025
CONNECT BIOPHARMA HOLDINGS LTD - DATA FROM RADEMIKIBART PHASE 2 TRIALS EXPECTED IN H1 2026
Source text: ID:nGNX6n7CSX
Further company coverage: CNTB.O
(((( Reuters.briefs@thomsonreuters.com ;));))
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。